Local Control Evaluation in Bone Metastases Treated with Stereotactic Body Radiation Therapy: Initial Experience

Clinical studies have showed the efficacy of SBRT for pain control with consequent improvement of quality of life, and also, secondary to local tumor control, a longer survival in oligometastases and oligo-recurrence disease. We present our initial experience using SBRT for bone metastases in oligometastases and oligo-recurrence patients. At the moment, we have treated ten lesions in nine patients. Patients in oligometastases or oligo-recurrence state, with localized bone metastasis, up to three separate sites were included by imaging study (bone scan, PET-CT, CT or MRI), in case of spinal lesions each of the separate sites may have a maximal involvement of two contiguous vertebral bodies. Patients were treated with high precision machines. Eight of them had a single bone lesion and one had two spinal lesions. Primary tumors were treated with curative intent by their respective protocol. The dose prescription was 16Gy in a single fraction or 22.5Gy in three fractions. Follow-up: 1, 3, 6, 12 and 24 months from treatment time, with physical examination, rating the pain at each visit and PET-CT at a second visit (three months from treatment). Currently we have a mean follow-up of six months (r1-19), with no adverse effect detected. The patient who had pain, showed a complete pain relief. All of these patients are in local tumor control. The SBRT for bone metastasis was well tolerated in this series, without toxicity at the moment, and complete local control in the ten lesions treated. Although this is a small series with short follow-up, it seems that long-term results can show us a new perspective in oligometastases and oligo-recurrence patients.Scientific Abstract 3762; TablePatient characteristicsAge distribution, y Min48 Mean57.2 Max67Sex distribution, n=9 Male1 Female8Histology Breast5 Colon1 Lung (ADK:SCLC)2 (1:1) Pancreas1 Open table in a new tab